Partnerships between pharma firms are critical for PD therapeutics, combining resources and expertise to reduce costs and accelerate development. These alliances drive innovation and market growth, especially for high-risk disease-modifying therapies (DMTs).
Biotech-pharma deals (e.g., Roche’s $2B 2023 licensing) merge agility with resources. 70% of PD pipelines now involve partnerships...
Portuguese 
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt